Investors & Media

News

June 30, 2022

NGM Bio Appoints Siobhan Nolan Mangini to President and Chief Financial Officer

June 23, 2022

NGM Bio to Host the Final of Four Virtual R&D Events on June 29, 2022

June 2, 2022

NGM Bio to Participate in Upcoming Investor Conferences

May 24, 2022

NGM Bio to Host the Third of Four Virtual R&D Events on May 31, 2022

May 12, 2022

NGM Bio Announces Initiation of Phase 1/1b Clinical Study of NGM438 for the Treatment of Patients with Advanced Solid Tumors

May 5, 2022

NGM Bio Provides Business Highlights and Reports First Quarter 2022 Financial Results

April 20, 2022

NGM Bio to Participate in Upcoming Investor Conferences

April 20, 2022

NGM Bio to Host the Second of Four Virtual R&D Events on April 27, 2022

April 8, 2022

NGM Bio to Present Late-Breaking Preclinical Research at 2022 AACR Annual Meeting Supporting Development of its Myeloid Reprogramming Portfolio

March 31, 2022

NGM Bio Announces Initiation of Phase 1/1b Clinical Trial of NGM831 for the Treatment of Patients with Advanced Solid Tumors

Displaying 1 - 10 of 18

Contact Information

investor relations

ir@ngmbio.com

media relations

media@ngmbio.com